TLR8

TLR8 Related Products (34):

By Type:	Pan (14) Selective (6)
By Effects:	Inhibitors (4) Agonists (22) Antagonists (4) Activators (3) Modulator (1)

Cat. No.	Product Name	Effect	Purity

HY-13740

Resiquimod	Agonist	99.95%
Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.

HY-134581

Enpatoran	Inhibitor	99.77%
Enpatoran (M5049) is a potent, orally active and dual TLR7/8 inhibitor with IC₅₀s of 11.1 nM and 24.1 nM in HEK293 cells, respectively. Enpatoran is inactive against TLR3, TLR4 and TLR9. Enpatoran can block molecule synthetic ligands and natural endogenous RNA ligands. Enpatoran exhibits excellent pharmacokinetic properties in vivo. Enpatoran can be used for both innate and adaptive autoimmunity blocking research .

HY-109104

Telratolimod	Agonist	98.98%
Telratolimod (MEDI9197) is a potent toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity.

HY-13773

Motolimod	Agonist	98.12%
Motolimod (VTX-2337;VTX-378) is a selective Toll-like receptor 8 (TLR8) agonist, with an EC₅₀ of approximately 100 nM.

HY-109137

Selgantolimod	Agonist	98.23%
Selgantolimod (GS-9688) is an orally active, potent and selective toll-like receptor 8 (TLR8) agonist for the treatment of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection.

HY-160228

ORN 02	Activator
ORN 02 is a synthetic single-stranded U-rich RNA and contains 6 repeats of UUAU sequence motif. The AU-rich oligoribonucleotides (ORNs) are able to stimulate TLR8.

HY-160228A

ORN 02 sodium	Activator
ORN 02 (sodium) is a synthetic single-stranded U-rich RNA and contains 6 repeats of UUAU sequence motif. The AU-rich oligoribonucleotides (ORNs) are able to stimulate TLR8.

HY-160229

ssRNA40 sodium	Activator
ssRNA40 (sodium) is a 20-mer phosphothioate protected single-stranded RNA oligonucleotide. ssRNA40 is a uridine-rich ssRNA derived from the HIV-1 long terminal repeat on activation of NK cells via TLR7/8^[1][2].

HY-134581A

Enpatoran hydrochloride	Inhibitor	99.33%
Enpatoran (M5049) hydrochloride is a potent, orally active and dual TLR7/8 inhibitor with IC₅₀s of 11.1 nM and 24.1 nM in HEK293 cells, respectively. Enpatoran hydrochloride is inactive against TLR3, TLR4 and TLR9. Enpatoran hydrochloride can block molecule synthetic ligands and natural endogenous RNA ligands. Enpatoran hydrochloride exhibits excellent pharmacokinetic properties in vivo. Enpatoran hydrochloride can be used for both innate and adaptive autoimmunity blocking research.

HY-117066

CL075	Agonist	99.25%
CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively.

HY-103697A

Gardiquimod diTFA	Agonist	≥99.0%
Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod diTFA could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 when used at concentrations below 10 μM.

HY-128799

CL097	Agonist	99.89%
CL097, a potent TLR7 and TLR8 agonist, induces pro-inflammatory cytokines in macrophages. CL097 induces NADPH oxidase priming, resulting in an increase of the fMLF-stimulated ROS production.

HY-101929

CU-CPT17e	Agonist	99.00%
CU-CPT17e is a potent multi-Toll-like receptor (TLR) agonist that activates TLR3, TLR8, and TLR9.

HY-112667

CU-CPT-9a	Antagonist	99.36%
CU-CPT-9a is a specific TLR8 antagonist, with an IC₅₀ of 0.5 nM.

HY-139323

TLR7/8-IN-1	Inhibitor	99.80%
TLR7/8-IN-1 is a crystalline from of a TLR7/TLR8 inhibitor extracted from patent WO2019220390, compound 2b. TLR7/8-IN-1 can be used for the research of autoimmune disease.

HY-112050

CU-CPT-8m	Antagonist	99.98%
CU-CPT-8m is a specific TLR8 antagonist, with an IC₅₀ of 67 nM.

HY-103698

TLR7/8 agonist 1	Agonist
TLR7/8 agonist 1 is a toll-like receptor (TLR7)/TLR8 dual-agonistic imidazoquinoline.

HY-130797

TLR7/8 agonist 3	Agonist	99.96%
TLR7/8 agonist 3 is a potent TLR7 and TLR8 agonist, extracted from patent WO2016057618 (compound of formula (II)).

HY-103697

Gardiquimod	Agonist	99.24%
Gardiquimod, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 when used at concentrations below 10 μM.

HY-139017

TLR7/8 agonist 4	Agonist	99.04%
TLR7/8 agonist 4 (compound 41) is a potent TLR7/8 agonist. TLR7/8 agonist 4 has anti-cancer activity.

Name
Email *

	Sorry, but the email address you supplied was invalid.